Informational only — Not medical advice. Always consult a licensed healthcare provider.

Shasthya স্বাস্থ্য · Health, made simple
বাং
Community data Updated 23 hours ago
🌐 বাংলায় দেখুন

Indications

Lenograstim is used in adults, adolescents and children older than 2 years. It has three uses. The first is to shorten how long neutropenia lasts in patients with non myeloid malignancy who are having myeloablative therapy followed by bone marrow transplantation (BMT), and who are thought to be at increased risk of prolonged severe neutropenia. Granocyte is also indicated for the same age groups. It is used to shorten the duration of severe neutropenia, and the complications that come with it, in patients having established cytotoxic therapy that carries a significant incidence of febrile neutropenia. Lenograstim also helps with mobilisation of peripheral blood progenitor cells (PBPCs), both in patients and in healthy donors.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Lenograstim is the glycosylated recombinant form of human granulocyte colony stimulating factor. After chemotherapy, it speeds up the recovery of neutrophils quite markedly, and this shows in clinical end-points such as how often laboratory-confirmed infection occurs and how long a patient stays in hospital. Patients on lenograstim have also been able to receive higher chemotherapy dose intensity, especially those with breast cancer or small cell lung cancer. Improvements in tumour response and survival, however, have not been demonstrated. Lenograstim also helps neutrophils recover in patients having a bone marrow transplant, and it stimulates the production of peripheral blood stem cells (PBSCs), which are used for autologous transfusion after aggressive chemotherapy.

Pregnancy & Breastfeeding

There isn't enough data on the use of lenograstim in pregnant women. Animal studies have shown reproductive toxicity, but the possible risk to humans is not known. So lenograstim should not be used during pregnancy unless it is clearly necessary.

It is not known whether lenograstim passes into human milk, and its excretion in milk has not been studied in animals. Breast-feeding should be stopped during treatment with lenograstim.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Lenograstim should only be given together with an experienced oncology and/or haematology centre. The recommended dose of Lenograstim is 19.2 MIU (150 µg) per m2 per day, which is therapeutically equivalent to 0.64 MIU (5 µg) per kg per day. This dose applies to peripheral stem cell or bone marrow transplantation, established cytotoxic chemotherapy, and PBPC mobilisation after chemotherapy. The 13 million IU/mL strength can be used in patients with a body surface area up to 0.7 m2. The 34 million IU/mL strength can be used in patients with a body surface area up to 1.8 m2. For PBPC mobilisation with Lenograstim alone, the recommended dose is 1.28 MIU (10 µg) per kg per day. Elderly: clinical trials with Lenograstim have included a small number of patients up to the age of 70 years. Special studies have not been performed in the elderly, so specific dosage recommendations cannot be made. Paediatric population: in children older than 2 years and in adolescents, the dose is the same as in adults. This applies when Lenograstim is used to reduce the duration of neutropenia after myeloablative therapy followed by BMT, or after cytotoxic chemotherapy.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.